A Clinical Study to Evaluate the Efficacy and Safety of Hemocoagulase Injection

Inclusion Criteria: * 18-75 years; * Hemoptysis \>=100 mL within 24 hours; * Bronchiectasis diagnosed by chest high resolution CT; * Patient, family or guardian is willing to sign the informed consent form. Exclusion Criteria: * With severe hepatic or renal insufficiency, ALT\>3 ULN, creatinine clearance \<30 mL/min or serum creatinine ≥200 µmol/L or ≥2.5 mg/dL; * Uncontrollable hypertension (SBP\>180mmHg or DBP\>110mmHg) or hypotension shock (SBP\<90 mmHg) at randomization; * History of thrombosis, patients who have undergone thrombosis, or who have severe hematologic diseases; * Patient with bleeding caused by DIC or vascular disease; * Patient with coagulation dysfunction 1. INR\>2 2. Patient with abnormal coagulation function or other bleeding disease (including clinical congenital bleeding disorders, such as von Willebrand disease or acquired hemophilia; hemorrhagic disease; and significant unexplained hemorrhagic disease) 3. Platelet count \<100×109 /L; * known allergic to aspirin, clopidogrel, heparin, snake venom blood clotting enzyme, or any component in the study drug allergy or allergic constitution; * Women who are pregnant or lactating and women of child-bearing agewho do not take reliable contraceptive measures; * Patients who are or are planning to participate in other clinical trials during the study period; * Within 72 hours before using the following products including Hemocoagulase For Injection (邦亭®), injection spearhead haemocoagulase (巴曲亭®), Haemocoagulase Agkistrodon for Injection (苏灵®), Hemocoagulase Atrox for Injection (立止血®), leaf pigment or other hemostatic agents; * Life expectancy of less than 3 months; * Any other patients who have been judged unfit to participate in this clinical study, including those who are unable or unwilling to comply with the protocol requirements; * Patients who had participated in other clinical studies within three months prior to the study.